Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Axitinib + pembrolizumab is approved by both the FDA and EMA as a first-line treatment for advanced or metastatic clear cell renal cell carcinoma (ccRCC). This combination became a standard frontline therapy following the KEYNOTE-426 phase III trial, which demonstrated superior overall survival and progression-free survival compared to sunitinib monotherapy in patients with advanced ccRCC
The treatment paradigm of clear metastatic cell renal cell carcinoma (mccRCC) has changed dramatically. From cytokines, IL-2 , and interferon-alpha to t…